Dr. David B. Agus, MD serves as a Research Director at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center. Dr. Agus serves as Medical Advisor of Keas Inc. He serves as a key adviser to CrossChx, Inc.'s executive team and contributes to the long-term goal of using technology to extend life expectancy. He serves as the Chief Executive Officer of USC's Lawrence J. Ellison Institute for Transformative Medicine. He co-founded Applied Proteomics, Inc. in 2006. He is a Co-founder of several personalized medicine companies. He was a Co-Founder of Navigenics, Inc. and served as its Research Director. He was the Founder of PeopleLivingwithCancer.org. He served as Chairman of Clinical Advisory Board of Navigenics, Inc. He serves as Chairman of the Scientific Advisory Board of Tempus Labs, Inc. He has been a Director of CrossChx, Inc. since October 12, 2016. He serves as a Director of Applied Proteomics, Inc. He serves as Member of Scientific Advisory Board of ProQuest Investments. He serves as a Member of Cancer Scientific Advisory Board of Progenics Pharmaceuticals, Inc. He served as a Director of Navigenics, Inc. He served as a Member of the Board of Directors at PeopleLivingwithCancer.org. He served as Member of Scientific Advisory Board at Aclara Biosciences Inc. since October 2003. Dr. Agus served as a Member of Scientific and Medical Advisory Board at CBR Systems, Inc. He served as a Member of Scientific Advisory Board at Monogram Biosciences, Inc. (formerly, Virologic, Inc.) and GeneOhm Sciences, Inc. He is Founding Director of USC's Lawrence J. Ellison Institute for Transformative Medicine. He has served in leadership roles at the World Economic Forum. Dr. Agus is a professor of medicine and engineering at the University of Southern California (USC) Keck School of Medicine and Viterbi School of Engineering. He is an Assistant Professor of Medicine at UCLA. He appears on television regularly as a medical contributor for CBS News. He is a New York Times bestselling author. "The End of Illness," Dr. Agus' first book published in 2012, is a New York Times #1 and international bestseller and was the subject of a television series on PBS. His most recent books "A Short Guide to a Long Life" and "The Lucky Years: How to Thrive in the Brave New World of Health" are also New York Times and international bestsellers. Well regarded for his innovations in medicine, Dr. Agus has built a reputation for taking a unique approach to looking at the relationship of the human body to health and disease. He is one of the world's leading physicians specializing in treating patients with advanced forms of cancer. Over the years, he has treated a number of high-profile patients, including Apple Co-Founder Steve Jobs, musician Neil Young and former U.S. Senator Ted Kennedy among many others. He earned a bachelor's degree in molecular biology from Princeton University and received an M.D. from the University of Pennsylvania School of Medicine and participated in a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. Dr. David B. Agus, MD serves as a Research Director at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center. Dr. Agus serves as Medical Advisor of Keas Inc. He serves as a key adviser to CrossChx, Inc.'s executive team and contributes to the long-term goal of using technology to extend life expectancy. He serves as the Chief Executive Officer of USC's Lawrence J. Ellison Institute for Transformative Medicine. He co-founded Applied Proteomics, Inc. in 2006. He is a Co-founder of several personalized medicine companies. He was a Co-Founder of Navigenics, Inc. and served as its Research Director. He was the Founder of PeopleLivingwithCancer.org. He served as Chairman of Clinical Advisory Board of Navigenics, Inc. He serves as Chairman of the Scientific Advisory Board of Tempus Labs, Inc. He has been a Director of CrossChx, Inc. since October 12, 2016. He serves as a Director of Applied Proteomics, Inc. He serves as Member of Scientific Advisory Board of ProQuest Investments. He serves as a Member of Cancer Scientific Advisory Board of Progenics Pharmaceuticals, Inc. He served as a Director of Navigenics, Inc. He served as a Member of the Board of Directors at PeopleLivingwithCancer.org. He served as Member of Scientific Advisory Board at Aclara Biosciences Inc. since October 2003. Dr. Agus served as a Member of Scientific and Medical Advisory Board at CBR Systems, Inc. He served as a Member of Scientific Advisory Board at Monogram Biosciences, Inc. (formerly, Virologic, Inc.) and GeneOhm Sciences, Inc. He is Founding Director of USC's Lawrence J. Ellison Institute for Transformative Medicine. He has served in leadership roles at the World Economic Forum. Dr. Agus is a professor of medicine and engineering at the University of Southern California (USC) Keck School of Medicine and Viterbi School of Engineering. He is an Assistant Professor of Medicine at UCLA. He appears on television regularly as a medical contributor for CBS News. He is a New York Times bestselling author. "The End of Illness," Dr. Agus' first book published in 2012, is a New York Times #1 and international bestseller and was the subject of a television series on PBS. His most recent books "A Short Guide to a Long Life" and "The Lucky Years: How to Thrive in the Brave New World of Health" are also New York Times and international bestsellers. Well regarded for his innovations in medicine, Dr. Agus has built a reputation for taking a unique approach to looking at the relationship of the human body to health and disease. He is one of the world's leading physicians specializing in treating patients with advanced forms of cancer. Over the years, he has treated a number of high-profile patients, including Apple Co-Founder Steve Jobs, musician Neil Young and former U.S. Senator Ted Kennedy among many others. He earned a bachelor's degree in molecular biology from Princeton University and received an M.D. from the University of Pennsylvania School of Medicine and participated in a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.

Blood Research & Hematologic Diseases